Glenmark Pharmaceuticals FY26 Annual Earnings Summary

Five observations from last FDA inspection remain unresolved; management is awaiting FDA response. This could delay injectable product launches and revenue.

Analyst highlighted past write-offs (Mondro, Zeta, antitrust) totaling significant amounts; management acknowledged but offered limited assurance on future controls.

Approval for Flovent 44 mcg and other respiratory ANDAs may be delayed, impacting Q4 US revenue expectations.

Glenmark USA is still defending against multiple antitrust lawsuits; settlement with direct purchaser class is subject to court approval, and other classes remain.

Reported India growth lagged secondary sales due to discontinuation of low-margin brands and diabetes underperformance; recovery expected only from Q3.

The AbbVie partnership is expected to close in September; any delay or renegotiation could impact cash position and IGI funding.

The three-tier distribution model caused a one-time 87% drop in primary sales due to inventory destocking; similar regulatory changes could recur.

ISB 2301 and three other multi-specific programs are preclinical; failure to advance or partner could impair value.

EM revenue declined 6.5% due to geopolitical issues in Latin America and West Africa; recovery uncertain.

While currency tailwinds boosted reported revenue, constant currency growth in Europe may be lower than reported 9.1%.

Excluding outlicensing income, gross margin was ~65%, impacted by product and geographic mix; recovery depends on new product approvals.

Despite progress, working capital days may face pressure from business growth and payment cycles in emerging markets.